L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
about
Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease.Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.DAT1 polymorphism determines L-DOPA effects on learning about others' prosociality.Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinationsAn update expert opinion on management and research strategies in Parkinson's disease psychosisPharmacogenetics of monoamine transporters.Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response.Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population.Pharmacogenetics-based new therapeutic concepts.Clinical aspects and management of levodopa-induced dyskinesia.Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.Levodopa-induced dyskinesias and their management.Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges.Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.Pharmacogenomics in neurology: current state and future steps.Parkinson's disease pharmacogenomics: new findings and perspectives.Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.Pharmacogenetics of drug response in Parkinson's disease.Pharmacogenetic considerations in the treatment of Parkinson's disease.The psychosis spectrum in Parkinson disease.How close are we to individualized medicine for Parkinson's disease?Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease.Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's diseaseFast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent regionally selective, bimodal effects on striatal dopamine kinetics in vivo.The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease.Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease.Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.Elevated dopamine in the medial prefrontal cortex suppresses cocaine seeking via D1 receptor overstimulation.Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.Gender effect on time to levodopa-induced dyskinesias.
P2860
Q34399250-B1012D2C-B872-434A-93D8-896BC5CD09F3Q34410406-E1576A4A-2BBA-4100-887F-328132DABB59Q34438073-06CF1A65-B22C-4523-8D9F-2DF1FAD4F4CAQ34826235-5307FC13-308C-4285-A404-FE45E644E186Q35124281-3E19867F-6037-4759-9299-EEF34AF10AF8Q35154278-8329764F-9D68-4E1F-9BD1-D7036174ACDFQ35207551-218F4A1C-94D6-4753-937E-1AF38EFF6112Q35814369-0402D3B0-96C8-4A0E-8868-97B6E892BD1EQ35821201-D7EE8802-2F65-41C0-B5AA-88F647F2354CQ35939972-102631A2-1713-4619-9C3C-087E3918C52AQ35956177-81F55FAB-CF12-4B76-AD3F-A982ACDE7051Q36022700-D0004AEB-E92C-48DC-87E4-0A5389300EC0Q36730631-FF211283-DDBA-46C3-B887-60A7DB365E47Q37280804-6B99B7AF-68E5-424D-BA3A-552A807DC993Q37583417-9FA24402-737E-45D9-A49D-C113623EBA73Q37853032-1E48D2E5-9BB5-4DBB-AA33-8C184B38D187Q37957393-8DF6E128-1112-4488-8E17-5C1003726204Q37967607-EFC98890-D6B5-4C9E-83B5-76C8158421E5Q38241678-EB9C186E-8E3B-46CC-A049-FC6C0E1D7BB0Q38245731-D0F218D5-C161-4AB8-973E-3FDA1DC0E6D6Q38250117-FA8E9156-B295-42C9-8439-8A3190D5E1A1Q38364825-58826A25-6D21-4CB8-AD5B-8127FB86EC9EQ38768169-8CB03645-AEE6-4C15-B4B8-07FA71DFC493Q38814888-5960EBFC-7138-4AF7-AB59-8E38E8CF5273Q38865983-F46BCBF6-285D-459C-A367-C6478B9186CBQ39273083-5B76439D-BCF7-4697-814D-19C828BE9320Q39516476-B9642E1B-8759-43F6-BF2C-92AC2DB597CAQ40136993-24FC0D15-3483-4711-8371-C40B445E7289Q41711967-7DC006B6-75AF-4264-AFDF-FB158BC26E9EQ42754446-9BC8B251-B878-4C9D-AC8C-E9DC96E327C5Q42792207-A4F797AA-476A-441E-B1AA-1EB3A3AE580EQ42859427-376A69C0-93EF-47D7-93C2-F8B1E79A820CQ44687266-870E2826-073C-498C-B81F-A8A58132A14EQ45007058-FABEAAEA-ADB6-48F3-827B-FBAF69F53F2AQ47389217-5B24565C-9AE9-4142-B575-380C77009B14Q47648607-E7076036-5821-4B19-B60E-A52257F64471Q47828012-93E75AAD-3685-43DF-B4FE-CFF3AB634F64Q48880365-6B3CC268-E008-4285-A34F-7BA1153F8829Q49197356-E0DD12D4-1E18-4FDB-83EF-8E736A606AAAQ51469422-0F677A7D-DA4A-4D63-9D49-624FF73BA392
P2860
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
@en
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
@nl
type
label
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
@en
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
@nl
prefLabel
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
@en
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
@nl
P2093
P1433
P1476
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism.
@en
P2093
Brockmöller J
Grapengiesser A
P304
P356
10.1212/01.WNL.0000068009.32067.A1
P407
P577
2003-06-01T00:00:00Z